U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow Jones up 0.37%, NASDAQ rising 1.07%, and S&P 500 increasing by 0.62%. Information technology shares led the rise, while materials stocks fell by 0.7%.
Darden Restaurants Financial Results: Darden Restaurants reported disappointing first-quarter earnings of $1.97 per share, missing the expected $2.00, and quarterly sales of $3.004 billion, below the $3.040 billion estimate.
Notable Stock Movements: 89bio, Inc. shares surged 86% after an acquisition announcement, while Intel Corporation's stock rose 27% following a partnership with NVIDIA. Conversely, Replimune Group, Inc. shares dropped 39% due to FDA feedback evaluation.
Economic Indicators: U.S. initial jobless claims fell to 231,000, lower than expected, and the Philadelphia Fed Manufacturing Index rose to +23.2, marking its highest level since January.
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.560
Low
3.00
Averages
11.43
High
18.00
Current: 7.560
Low
3.00
Averages
11.43
High
18.00
BMO Capital
Evan Seigerman
Underperform
to
Market Perform
upgrade
$2 -> $11
2025-11-03
Reason
BMO Capital
Evan Seigerman
Price Target
$2 -> $11
AI Analysis
2025-11-03
upgrade
Underperform
to
Market Perform
Reason
BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$12
2025-10-27
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12
2025-10-27
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Replimune to Buy from Neutral with a $12 price target after the company resubmitted the biologics license application for RP1 plus Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The firm increased its probability of approval of RP1 plus Opdivo in anti-PD1 failed melanoma patients to 85% from 50%. The FDA indicated that this resubmission is considered a comprehensive response to the complete response letter received in July, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL
Unlock Now
Wedbush
Neutral -> Outperform
upgrade
$4 -> $18
2025-10-20
Reason
Wedbush
Price Target
$4 -> $18
2025-10-20
upgrade
Neutral -> Outperform
Reason
Wedbush upgraded Replimune to Outperform from Neutral with a price target of $18, up from $4.
Wedbush
Neutral -> Outperform
upgrade
$4 -> $18
2025-10-20
Reason
Wedbush
Price Target
$4 -> $18
2025-10-20
upgrade
Neutral -> Outperform
Reason
As previously reported, Wedbush upgraded Replimune to Outperform from Neutral with a price target of $18, up from $4. The firm notes the company announced FDA acceptance of BLA submission for RP1 plus nivolumab in advanced melanoma, with a PDUFA date for April 10, 2026, based on an FDA Class II resubmission timeline. The submission is considered to be a complete response to the CRL that Replimune received in July this year. Wedbush views the FDA turnaround following a Type A meeting with Replimune as highly promising. The firm says it has to assume that the FDA has given somewhat of a green light for the re-submission, which includes additional information.
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
